KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other financing activities (2016)

Novavax has reported Other financing activities over the past 5 years, most recently at $10.0 million for Q3 2016.

  • Quarterly results put Other financing activities at $10.0 million for Q3 2016, changed N/A from a year ago — trailing twelve months through Sep 2017 was $10.0 million (down 50.0% YoY), and the annual figure for FY2016 was $10.0 million, changed.
  • Other financing activities for Q3 2016 was $10.0 million at Novavax, roughly flat from $10.0 million in the prior quarter.
  • Over the last five years, Other financing activities for NVAX hit a ceiling of $11.6 million in Q1 2015 and a floor of -$755000.0 in Q1 2012.
  • Median Other financing activities over the past 5 years was -$1000.0 (2012), compared with a mean of $3.8 million.
  • Biggest five-year swings in Other financing activities: soared 1160100.0% in 2015 and later dropped 14.09% in 2016.
  • Novavax's Other financing activities stood at -$1000.0 in 2012, then changed by 0.0% to -$1000.0 in 2013, then changed by 0.0% to -$1000.0 in 2014, then soared by 1160100.0% to $11.6 million in 2015, then dropped by 14.09% to $10.0 million in 2016.
  • The last three reported values for Other financing activities were $10.0 million (Q3 2016), $10.0 million (Q1 2016), and $11.6 million (Q1 2015) per Business Quant data.